Thomas Reiser/X
Aug 28, 2025, 18:38
ISTH Survey: APS Diagnosis and Antithrombotic Treatment in Acute Ischemic Cardiac Disease
Thomas Reiser, Executive Director of the International Society on Thrombosis and Haemostasis (ISTH), shared a post on X:
”Your expertise is requested.
Take this survey from the ISTH SSC Subcom. on Lupus Anticoagulant/Antiphospholipid Antibodies on APS diagnosis and antithrombotic treatment in patients with acute ischemic cardiac disease to assess current clinical practices.”
Stay updated with Haemostasis Today.
-
Nov 2, 2026, 18:08Jonathan Penm: Antithrombotic Stewardship Optimizes VTE Prophylaxis in ICU Patients
-
Nov 2, 2026, 14:48Heghine Khachatryan: Vitamin B12 Replacement Choosing the Right Route for Each Patient
-
Nov 2, 2026, 14:28Anastasia Conti: ASH Global Research Award Backs New Directions in AML Research
-
Nov 2, 2026, 14:22Sara Zalghout: Linking Bacterial Virulence to NETosis and Thromboinflammation
-
Nov 2, 2026, 13:58Functional Iron Deficiency: From Iron Sequestration to Therapeutic Targeting
-
Nov 2, 2026, 13:56Jan Terje Andersen: Albumin Engineering Opens New Routes for Erythropoietin Delivery
-
Nov 2, 2026, 13:44Rishiraj Sinha: Strengthening ISBT–AABB Collaboration in Transfusion Medicine
-
Nov 2, 2026, 13:28Jeremiah Morris: Why Blood Detection Reagents Work Better on Dry Bloodstains
-
Nov 2, 2026, 12:38Maria Τektonidou: Machine Learning – A New Approach to CVD Risk in SLE